Skinjectables® now offers Kybella®.
Skinjectables® of Tucson now offers Kybella®, a non-invasive, injectable treatment that targets and destroys fat that is stored under the chin and neck area as well as smaller areas of stubborn, unwanted fat deposits virtually anywhere on the body!.
With minimal downtime, non-invasive Kybella can reduce that double chin and help sculpt your jawline permanently! It can banish the bra bulge, melt away those banana rolls under the buttocks, fine-tune your inner thighs for that coveted “thigh gap”, shrink saddle bags (outer thigh puffs), eliminate fatty knee pockets…..and the list goes on!
Who is Kybella® for?
FDA approved Kybella for submental fullness is ideal for patients with moderate to severe chin fullness who are looking to sculpt their jaw line but who aren’t interested in more invasive procedures. Kybella is performed as a series of 2-6 treatments spaced 4-8 weeks apart. Each treatment takes approximately 15 to 20 minutes to complete with most people experiencing minimal discomfort during treatment. The most common side effects following treatment with Kybella are moderate to significant swelling lasting several days and mild swelling lasting a few weeks; mild injection site bruising; potential local numbness, tenderness, and nodules which resolve over time.
What is Kybella®?
Kybella is a solution of deoxycholic acid, a naturally occurring enzyme in our bodies that is responsible for breaking down and absorbing fat. When injected, Kybella permanently destroys fat cells, targeting and liquefying subcutaneous fat which is then eliminated naturally from your body. Once treated, fat cells are eliminated and thus no longer able to accumulate and store fat—giving you a sculpted jawline or significant improvement to the treated area. Additionally, unlike other treatments which can leave the skin around the treated area loose and sagging, Kybella stimulates local collagen production—which, in turn, shrinks and tightens skin.
For more information, please call Skinjectables at (520) 395-1245.